Eli Lilly CEO expects new weight loss pill to be approved next year
1. Eli Lilly's weight loss pill, orforglipron, may receive FDA approval early next year. 2. Key late-stage trial data is expected by mid-year, crucial for market entry. 3. Eli Lilly competes with Novo Nordisk for dominance in the weight loss drug market. 4. Orforglipron showed a 14.7% weight loss in trials, outperforming placebo results.